Overview

Study of Weekly LOC-paclitaxel Injection for Melanoma

Status:
Terminated
Trial end date:
2016-02-01
Target enrollment:
Participant gender:
Summary
The goal of this clinical research study is to find the highest tolerable dose of LOC-paclitaxel when given to patients with metastatic melanoma. The safety of this drug and if it can control the disease is also being studied.
Phase:
Phase 1
Details
Lead Sponsor:
M.D. Anderson Cancer Center
Collaborators:
American Regent, Inc.
Luitpold Pharmaceuticals
Treatments:
Albumin-Bound Paclitaxel
Paclitaxel